Barchart.com
Your browser of choice has not been tested for use with Barchart.com. If you have issues, please download one of the browsers listed here.
Join Barchart Premier for advanced OPTIONS screeners and volatility tools. FREE 30 Day Trial
Menu
Stocks | Futures | Watchlist | More
 
or
Watchlist | Portfolio
Site News
Contact
Market:

Autolus Therapeutics Plc ADR (AUTL)

Autolus Therapeutics Plc ADR (AUTL)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] by (Cboe BZX)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] [[ item.lastPriceExt ]] [[ item.priceChangeExt ]] ([[ item.percentChangeExt ]]) [[ item.tradeTimeExt ]]
News & Headlines for [[ item.sessionDateDisplayLong ]]
Notes
Alerts
Watch
Help
Go To:
AUTL
Chart of the Day: Autolus Therapeutics - Effective Cancer Treatments Barchart - Fri Jan 12, 7:00AM CST

The Chart of the Day belongs to the oncology based biomedical company Autolus Therapeutics (AUTL) . I found the stock by using Barchart's powerful screening functions to find stocks with the highest technical...

AUTL : 3.49 (+3.25%)
Why Autolus Therapeutics Stock Is Crashing Today Motley Fool - Fri Dec 9, 2022

Shares of Autolus Therapeutics (NASDAQ: AUTL) were crashing 35.9% as of 10:34 a.m. ET on Friday. The steep decline came after the biopharmaceutical company announced the price of a public stock offering...

AUTL : 3.49 (+3.25%)
R&D Efforts to Improve Optimal Treatments for Advanced Pancreatic Ductal Adenocarcinoma (PDAC) Progressing FinancialNewsMedia - Wed Oct 5, 2022

Palm Beach, FL – October 5, 2022 – FinancialNewsMedia.com News Commentary – Advanced pancreatic ductal adenocarcinoma (PDAC) remains a significant cause of mortality accounting for up to 4% of all...

ONCY : 1.0100 (+2.02%)
ONC.TO : 1.37 (unch)
SNTI : 0.3212 (-17.64%)
INBX : 13.41 (-1.14%)
IMVT : 27.00 (+1.81%)
AUTL : 3.49 (+3.25%)
BMY : 40.32 (-0.32%)
R&D Efforts to Improve Optimal Treatments for Advanced Pancreatic Ductal Adenocarcinoma (PDAC) Progressing PR Newswire - Wed Oct 5, 2022

/PRNewswire/ -- FinancialNewsMedia.com News Commentary - Advanced pancreatic ductal adenocarcinoma (PDAC) remains a significant cause of mortality accounting...

BMY : 40.32 (-0.32%)
ONC.TO : 1.37 (unch)
ONCY : 1.0100 (+2.02%)
SNTI : 0.3212 (-17.64%)
INBX : 13.41 (-1.14%)
IMVT : 27.00 (+1.81%)
AUTL : 3.49 (+3.25%)
Correction - Autolus Therapeutics to Report Second Quarter 2022 Financial Results on August 4, 2022 Globe Newswire - Thu Jul 21, 2022

In the previous version the link to register for the conference call was incorrect – this press release contains the correct link to register for the call,...

AUTL : 3.49 (+3.25%)
Autolus Therapeutics to Report Second Quarter 2022 Financial Results on August 4, 2022 Globe Newswire - Thu Jul 21, 2022

LONDON, July 21, 2022 (GLOBE NEWSWIRE) -- Autolus Therapeutics plc (Nasdaq: AUTL), a clinical-stage biopharmaceutical company developing next-generation...

AUTL : 3.49 (+3.25%)
Autolus Therapeutics to Participate in William Blair’s Biotech Focus Conference 2022, New York, July 12 – 13, 2022 Globe Newswire - Wed Jul 6, 2022

LONDON, July 06, 2022 (GLOBE NEWSWIRE) -- Autolus Therapeutics plc (Nasdaq: AUTL), a clinical-stage biopharmaceutical company developing next-generation...

AUTL : 3.49 (+3.25%)
Autolus Therapeutics Presents Clinical Data Updates at the European Hematology Association Congress Globe Newswire - Fri Jun 10, 2022

- AUTO4 shows high level of clinical activity with a novel targeting approach for patients with T Cell Lymphoma- AUTO1/22 demonstrates encouraging and...

AUTL : 3.49 (+3.25%)
Autolus to hold Annual General Meeting (AGM) of Shareholders on Tuesday, June 28, 2022 Globe Newswire - Tue May 31, 2022

LONDON, May 31, 2022 (GLOBE NEWSWIRE) -- Autolus Therapeutics plc (Nasdaq: AUTL), a clinical-stage biopharmaceutical company developing next-generation...

AUTL : 3.49 (+3.25%)
Autolus Therapeutics to Participate in the Jefferies Healthcare Conference, being held in New York from June 8 – 10, 2022 Globe Newswire - Fri May 27, 2022

LONDON, May 27, 2022 (GLOBE NEWSWIRE) -- Autolus Therapeutics plc (Nasdaq: AUTL), a clinical-stage biopharmaceutical company developing next-generation...

AUTL : 3.49 (+3.25%)

Barchart Exclusives

1 No-Brainer Value Stock That Looks Set to Recover From Its Slump Barchart - 53 minutes ago
PayPal's valuations look quite compelling after its massive underperformance, and the fintech name looks like a good value stock to buy at these price levels. Read more
Want to use this as
your default charts setting?
Save this setup as a Chart Templates
Switch the Market flag
for targeted data from your country of choice.
Open the menu and switch the
Market flag for targeted data from your country of choice.
Want Streaming Chart Updates?
Switch your Site Preferences
to use Interactive Charts
Need More Chart Options?
Right-click on the chart to open the Interactive Chart menu.

Free Barchart Webinar

[[ data.userDate ]]
[[ data.eventTime | date: 'EEE, MMM dd, yyyy h:mm a' ]] [[ zone ]]
Reserve Your Spot